Xilio Therapeutics, Inc. (XLO)
Nasdaq: XLO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 23, 2026 | Mar 11, 2025 | Apr 1, 2024 | Mar 2, 2023 | Mar 1, 2022 | · |
| Revenue | 43,766 | 6,344 | · | · | · | · |
| Research and development | 56,039 | 41,211 | 52,136 | 59,201 | 51,188 | 43,910 |
| General and administrative | 29,709 | 24,778 | 26,997 | 29,948 | 23,856 | 10,653 |
| Total operating expenses | 85,748 | 66,926 | 79,133 | 89,149 | 75,044 | 54,563 |
| Operating income | -41,982 | -60,582 | -79,133 | -89,149 | -75,044 | -54,563 |
| Other income (expense), net | 1,101 | 2,341 | 2,729 | 927 | -756 | -656 |
| Total non-operating income (expense) | 6,946 | 2,341 | 2,729 | 927 | -756 | · |
| Income before income taxes | -35,036 | -58,241 | · | · | · | · |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income including non-controlling interests | -35,036 | -58,241 | -76,404 | -88,222 | -75,800 | -55,219 |
| Net income | -35,036 | -58,241 | -76,404 | -88,222 | -75,800 | -55,219 |
| Earnings per share, basic | -4.19 | -15.24r | -38.92b | -45.08b | -189.28b | -1,475.88b |
| Earnings per share, diluted | -4.19 | -15.24r | -38.92b | -45.08b | -189.28b | -1,475.88b |
| Weighted average shares, basic | 8,359,109 | 3,822,244r | 1,964,008b | 1,956,578b | 400,451b | 37,413b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-14 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic